AU2009245785A1 - Encapsulation of biologically active agents - Google Patents

Encapsulation of biologically active agents Download PDF

Info

Publication number
AU2009245785A1
AU2009245785A1 AU2009245785A AU2009245785A AU2009245785A1 AU 2009245785 A1 AU2009245785 A1 AU 2009245785A1 AU 2009245785 A AU2009245785 A AU 2009245785A AU 2009245785 A AU2009245785 A AU 2009245785A AU 2009245785 A1 AU2009245785 A1 AU 2009245785A1
Authority
AU
Australia
Prior art keywords
biologically active
antibody
active agent
particulate carrier
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009245785A
Other languages
English (en)
Inventor
Mehmet Fidanboylu
Irene Papanicolaou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2009245785A1 publication Critical patent/AU2009245785A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009245785A 2008-05-06 2009-05-05 Encapsulation of biologically active agents Abandoned AU2009245785A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US61/050,775 2008-05-06
US7417108P 2008-06-20 2008-06-20
US61/074,171 2008-06-20
PCT/EP2009/055437 WO2009135854A2 (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents

Publications (1)

Publication Number Publication Date
AU2009245785A1 true AU2009245785A1 (en) 2009-11-12

Family

ID=43125568

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009245785A Abandoned AU2009245785A1 (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents

Country Status (11)

Country Link
US (1) US20110059167A1 (https=)
EP (1) EP2271324A2 (https=)
JP (1) JP2011519893A (https=)
CN (1) CN102083423A (https=)
AU (1) AU2009245785A1 (https=)
BR (1) BRPI0912536A2 (https=)
EA (1) EA201001567A1 (https=)
IL (1) IL208666A0 (https=)
MX (1) MX2010012141A (https=)
WO (1) WO2009135854A2 (https=)
ZA (1) ZA201007437B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088963A (zh) * 2008-05-06 2011-06-08 葛兰素集团有限公司 生物活性剂的囊封方法
JP6470740B2 (ja) * 2013-06-07 2019-02-13 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム
EP3377115A2 (en) * 2015-11-20 2018-09-26 AbbVie Deutschland GmbH & Co. KG Surface-modified nanospheres encapsulating antigen-binding molecules
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017789A1 (en) * 1993-02-15 1994-08-18 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
AU7655194A (en) * 1993-09-09 1995-03-27 Schering Aktiengesellschaft Active principles and gas containing microparticles
DE69819145T2 (de) * 1997-04-17 2004-08-19 Amgen Inc., Thousand Oaks Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
US7332159B2 (en) * 2004-09-30 2008-02-19 Board Of Regents Of The University Of Nebraska Method and composition for inhibiting reperfusion injury in the brain
US7597907B2 (en) * 2004-11-05 2009-10-06 Trustees Of The University Of Pennsylvania Antioxidant polymer nanocarriers for use in preventing oxidative injury

Also Published As

Publication number Publication date
BRPI0912536A2 (pt) 2018-10-16
US20110059167A1 (en) 2011-03-10
EA201001567A1 (ru) 2011-08-30
IL208666A0 (en) 2010-12-30
EP2271324A2 (en) 2011-01-12
CN102083423A (zh) 2011-06-01
MX2010012141A (es) 2010-12-17
ZA201007437B (en) 2012-03-28
JP2011519893A (ja) 2011-07-14
WO2009135854A3 (en) 2010-11-04
WO2009135854A2 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
EP2441447A1 (en) Encapsulation of biologically active agents
US20110059142A1 (en) Encapsulation of biologically active agents
Zaman et al. Nanoparticle formulations that allow for sustained delivery and brain targeting of the neuropeptide oxytocin
Yandrapu et al. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab
Ye et al. Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits
Kim et al. Intraocular distribution and kinetics of intravitreally injected antibodies and nanoparticles in rabbit eyes
US20230414716A1 (en) Sustained release formulations using non-aqueous emulsions
US20110059167A1 (en) Encapsulation of biologically active agents
Hamdi et al. Drug-loaded nanocarriers for back-of-the-eye diseases-formulation limitations
US20110064819A1 (en) Encapsulation of biologically active agents
US12239687B2 (en) Sustained release formulations using non-aqueous membrane emulsification
CN105338961A (zh) 制备包含治疗性蛋白质的颗粒的方法
Zhang Kinetics of polymeric nanoparticulate carriers and cargo under physiological and pathological conditions in the retina

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period